S&P 500 may face selling pressure as systematic funds reach full exposure
Relay Therapeutics, Inc. (NASDAQ:RLAY), currently valued at $620 million and trading below its InvestingPro Fair Value, saw Chief Financial Officer Thomas Catinazzo sell a total of $74,000 in company stock, according to a Form 4 filing with the Securities and Exchange Commission. The sales occurred in two separate transactions on July 28 and July 29, 2025, with prices ranging from $3.68 to $3.74. Analyst targets for the stock range from $4 to $29, suggesting potential upside.
On July 28, Catinazzo sold 1,701 shares of common stock at $3.74 per share. Following this transaction, Catinazzo directly owned 353,675 shares, including 200,516 shares underlying restricted stock units.
The second sale, which took place on July 29, involved 18,380 shares sold at $3.68 per share. After this transaction, Catinazzo directly owned 335,295 shares, which includes 158,123 shares underlying restricted stock units.
According to the footnotes in the SEC filing, the sales were executed to cover income tax withholding obligations upon the vesting of restricted stock units, and Catinazzo had no discretion over these transactions, which were conducted in accordance with Relay Therapeutics’ policies. For deeper insights into RLAY’s financial health, which InvestingPro rates as FAIR, and access to comprehensive analysis, subscribers can view the full Pro Research Report covering 30+ key metrics.
In other recent news, Relay Therapeutics has reported promising updates regarding its investigational drug RLY-2608, aimed at treating PIK3CA-mutated metastatic breast cancer. The company presented this data at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting. The results highlighted a median progression-free survival (PFS) of 10.3 months overall and 11.0 months specifically in second-line patients. This indicates an improvement in the treatment’s effectiveness, particularly in patients with PIK3CA kinase-domain mutations. Additionally, the ReDiscover trial showed an increase in median progression-free survival by seven months, with an overall improvement of 1.1 months compared to earlier updates. Following these developments, Citizens JMP analysts reaffirmed their Market Outperform rating for Relay Therapeutics, maintaining the price target at $12.00. The consistent data and positive analyst outlook reflect a strong potential for Relay Therapeutics’ ongoing research efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.